Pharsight

Zipsor patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7662858 ASSERTIO Method of treating post-surgical acute pain
Feb, 2029

(5 years from now)

US8110606 ASSERTIO Method of treating post-surgical acute pain
Feb, 2029

(5 years from now)

US7884095 ASSERTIO Method of treating post-surgical acute pain
Feb, 2029

(5 years from now)

US7939518 ASSERTIO Method of treating post-surgical acute pain
Feb, 2029

(5 years from now)

US8623920 ASSERTIO Method of treating post-surgical acute pain
Feb, 2029

(5 years from now)

US9561200 ASSERTIO Method of treating post-surgical acute pain
Feb, 2029

(5 years from now)

Zipsor is owned by Assertio.

Zipsor contains Diclofenac Potassium.

Zipsor has a total of 6 drug patents out of which 0 drug patents have expired.

Zipsor was authorised for market use on 16 June, 2009.

Zipsor is available in capsule;oral dosage forms.

Zipsor can be used as diclofenac potassium for relief of mild to moderate acute pain, nonsteroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain.

The generics of Zipsor are possible to be released after 24 February, 2029.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) May 25, 2024

Drugs and Companies using DICLOFENAC POTASSIUM ingredient

Market Authorisation Date: 16 June, 2009

Treatment: Nonsteroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain; Diclofenac potassium for relief of mild to moderate acute pain

Dosage: CAPSULE;ORAL

How can I launch a generic of ZIPSOR before it's drug patent expiration?
More Information on Dosage

ZIPSOR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic